BACKGROUND & AIM: The dopaminergic pathways have been implicated in the etiology of drug addictions. The aim of this study was to determine if variants in dopaminergic genes are associated with heroin addiction. MATERIALS & METHODS: The study includes 828 former heroin addicts and 232 healthy controls, of predominantly European ancestry. Ninety seven SNPs (13 genes) were analyzed. RESULTS: Nine nominally significant associations were observed at CSNK1E, ANKK1, DRD2 and DRD3. CONCLUSION: The results support our previous report of association of CSNK1E SNP rs1534891 with protection from heroin addiction. CSNK1E interacts with circadian rhythms and DARPP-32 and has been implicated in negative regulation of sensitivity to opioids in rodents. It may be a target for drug addiction treatment. Original submitted 8 August 2014; Revision submitted 8 October 2014.
BACKGROUND & AIM: The dopaminergic pathways have been implicated in the etiology of drug addictions. The aim of this study was to determine if variants in dopaminergic genes are associated with heroin addiction. MATERIALS & METHODS: The study includes 828 former heroin addicts and 232 healthy controls, of predominantly European ancestry. Ninety seven SNPs (13 genes) were analyzed. RESULTS: Nine nominally significant associations were observed at CSNK1E, ANKK1, DRD2 and DRD3. CONCLUSION: The results support our previous report of association of CSNK1E SNP rs1534891 with protection from heroin addiction. CSNK1E interacts with circadian rhythms and DARPP-32 and has been implicated in negative regulation of sensitivity to opioids in rodents. It may be a target for drug addiction treatment. Original submitted 8 August 2014; Revision submitted 8 October 2014.
Authors: Camron D Bryant; Melissa E Graham; Margaret G Distler; Michaelanne B Munoz; Dongdong Li; Paul Vezina; Greta Sokoloff; Abraham A Palmer Journal: Psychopharmacology (Berl) Date: 2008-12-03 Impact factor: 4.530
Authors: Colin A Hodgkinson; Qiaoping Yuan; Ke Xu; Pei-Hong Shen; Elizabeth Heinz; Elizabeth A Lobos; Elizabeth B Binder; Joe Cubells; Cindy L Ehlers; Joel Gelernter; John Mann; Brien Riley; Alec Roy; Boris Tabakoff; Richard D Todd; Zhifeng Zhou; David Goldman Journal: Alcohol Alcohol Date: 2008-05-12 Impact factor: 2.826
Authors: Weihua Huang; Thomas J Payne; Jennie Z Ma; Joke Beuten; Randolph T Dupont; Naohiro Inohara; Ming D Li Journal: Neuropsychopharmacology Date: 2008-03-19 Impact factor: 7.853
Authors: Andrea Vereczkei; Zsolt Demetrovics; Anna Szekely; Peter Sarkozy; Peter Antal; Agnes Szilagyi; Maria Sasvari-Szekely; Csaba Barta Journal: PLoS One Date: 2013-06-28 Impact factor: 3.240
Authors: Orna Levran; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek Journal: Ann Hum Genet Date: 2015-02-27 Impact factor: 1.670
Authors: Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye Journal: Curr Oncol Rep Date: 2020-02-06 Impact factor: 5.075
Authors: L R Goldberg; S L Kirkpatrick; N Yazdani; K P Luttik; O A Lacki; R K Babbs; D F Jenkins; W E Johnson; C D Bryant Journal: Genes Brain Behav Date: 2017-07-06 Impact factor: 3.449
Authors: Matthew Randesi; Wim van den Brink; Orna Levran; Vadim Yuferov; Peter Blanken; Jan M van Ree; Jurg Ott; Mary Jeanne Kreek Journal: Pharmacogenomics Date: 2017-12-06 Impact factor: 2.533
Authors: Matthew Randesi; Orna Levran; Joel Correa da Rosa; Julia Hankins; Jody Rule; Mary Jeanne Kreek; William M Lee Journal: Cell Mol Gastroenterol Hepatol Date: 2017-01-24